M&A Analysis – Deals March On In Big Month For Boston Scientific
Medtech Insight recorded 17 merger or acquisition deals in March, a rise from the nine deals recorded last month and in the same period last year. It was a busy month for Boston Scientific, which racked up two acquisitions, paying $460m for urology device maker NxThera and an undisclosed price for endoscopy firm EMcision.
You may also be interested in...
The UK’s NICE has recommended the use of Boston Scientific’s Rezum system for treatment of enlarged prostate. The minimally invasive procedure involves injecting steam to destroy excess prostate tissue.
Boston Scientific has expanded its gynecology/urology portfolio with the acquisition of nVision Medical, the maker of the first US FDA-cleared device designed to collect cell samples from the fallopian tubes for early ovarian cancer diagnosis.
In its second acquisition deal this month, Boston Scientific has agreed to pay up to $406m for NxThera, maker of the Rezῡm system for treating benign prostatic hyperplasia.